- Home
- TW vs BIIB Comparison
TW vs BIIB Comparison
Compare TW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TW
- BIIB
- Stock Information
- Founded
- TW 1996
- BIIB 1978
- Country
- TW United States
- BIIB United States
- Employees
- TW N/A
- BIIB N/A
- Industry
- TW Investment Bankers/Brokers/Service
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TW Finance
- BIIB Health Care
- Exchange
- TW Nasdaq
- BIIB Nasdaq
- Market Cap
- TW 27.5B
- BIIB 25.1B
- IPO Year
- TW 2019
- BIIB 1991
- Fundamental
- Price
- TW $132.45
- BIIB $156.19
- Analyst Decision
- TW Strong Buy
- BIIB Buy
- Analyst Count
- TW 15
- BIIB 27
- Target Price
- TW $131.93
- BIIB $252.20
- AVG Volume (30 Days)
- TW 804.4K
- BIIB 1.5M
- Earning Date
- TW 02-04-2025
- BIIB 10-30-2024
- Dividend Yield
- TW 0.31%
- BIIB N/A
- EPS Growth
- TW 21.01
- BIIB 10.05
- EPS
- TW 2.08
- BIIB 11.06
- Revenue
- TW $1,630,279,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- TW $33.54
- BIIB N/A
- Revenue Next Year
- TW $16.06
- BIIB N/A
- P/E Ratio
- TW $62.86
- BIIB $14.23
- Revenue Growth
- TW 29.40
- BIIB N/A
- 52 Week Low
- TW $86.06
- BIIB $153.62
- 52 Week High
- TW $141.69
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- TW 49.00
- BIIB 34.89
- Support Level
- TW $125.06
- BIIB $158.44
- Resistance Level
- TW $141.69
- BIIB $162.62
- Average True Range (ATR)
- TW 3.33
- BIIB 3.52
- MACD
- TW -0.69
- BIIB 0.66
- Stochastic Oscillator
- TW 38.16
- BIIB 32.53
About TW Tradeweb Markets Inc.
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in U.S. and European government debt, mortgage-backed securities, interest-rate swaps, and U.S. and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.